Subscription Required

Only paid subscribers* to Drug Benefit News can access this Web portal with three years of back issues, searchable article archives and other valuable resources.

Subscribers to Drug Benefit News receive

  • 24 biweekly issues (8 pages) of timely news and insightful strategies for reducing costs and improving outcomes, delivered First Class by U.S. Mail and electronically
  • Special E-Alerts when timely news breaks
  • Access to your subscriber-only web page with:
    • A posting of the latest issue
    • Searchable archives of all articles for the past three years
    • A chronological posting of back issues for three years
  • Recent stories of interest and hot topic articles grouped for convenient reading and regular postings from your editor
View a sample and get more information
January 23, 2015

Recent Stories of Interest

From Drug Benefit News - Responding to large increases in use and spend associated with compounded medications, Catamaran Corp. was one of several PBMs that took immediate steps last year to address this largely unregulated pharmacy practice by implementing prior authorization criteria and other restrictions on select products. Now taking that effort one step further, Catamaran has teamed up with United Compounding Management (UCM) to roll out what it’s calling the industry’s first-ever compound credentialing program and put some “discipline into a growing segment of pharmacy practice,” Catamaran Senior Vice President, Industry Relations & Supply Chain Management, Albert Thigpen, R.Ph., tells DBN. Read more

As health plans and PBMs keep close watch on biologics in the… Read more

Following last month’s approval of AbbVie Inc.’s hepatitis C therapy Viekira Pak… Read more

2015 Outlook Aggressive formulary management will continue to play a key role in… Read more

From the Editor

Welcome to your Drug Benefit News subscriber-only Web page

Be sure to visit often, for PDFs of issues, archives of articles and data, and more!

Please e-mail me with comments on the last issue of Drug Benefit News, story ideas for future issues or any other suggestions you have that can make the newsletter more useful for you.

January 8, 2015
Drug Channels Analyzes New PBM/Hep C Deals

Drug Channels estimates CVS, Express Scripts could be making $2,600 to $3,100 per patient on new hep C deals.

January 5, 2015
ODAC Meeting Materials Look Positive for Sandoz Biosimilar

Ahead of Wednesday meeting, ODAC materials indicate Sandoz’s biosimilar filgrastim is “highly similar” to Amgen’s Neupogen

December 22, 2014
Express Scripts Adds Viekira Pak to National Preferred Formulary

Express Scripts makes newly approved Viekira Pak exclusive option for genotype 1 hep C patients.

Updated Regularly

Featured Hot Topics

Search for your own Hot Topics

It's quick and easy to sign up for FREE access to!

Why do I need to register?